Venus Remedies shares surge 6% on UNICEF tender for Ceftriaxone drug

Madhu Balaji Updated - June 13, 2024 at 11:23 AM.

Shares of Venus Remedies surged about 6 per cent on the NSE following the receipt of tender from UNICEF for its antibiotic drug Ceftriaxone 1 mg.

According to Venus Remedies’ stock exchange disclosure, this follows the receipt of GMP (Good Manufacturing Practices) approval from UNICEF.

The stock of Venus Remedies traded at ₹374.50 on the NSE, higher by 5.69 per cent as of 10.06 am.

Sign up for newsletters, unlock features and do more on The Hindu
LOG IN
Support our reporting.
SUBSCRIBE NOW

The company had declared its financial results for the quarter ended March 2024 recording its consolidated net profit at ₹10.51 crore as against ₹11.06 crore in the corresponding quarter last year.

Published on June 13, 2024 05:53
Tags

This is a Premium article available exclusively to our subscribers.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
If you're already a subscriber
Access just this article

You have reached your free article limit.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
If you're already a subscriber
Access just this article

You have reached your free article limit.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
or read this article by Downloading TheHindu Businessline News app
If you're already a subscriber
Access just this article

TheHindu Businessline operates by its editorial values to provide you quality journalism.

Support our reporting.
Subscribe
This is your last free article.
to read unlimited content from TheHindu Businessline
Subscribe
Stay updated on Markets,Economy, Agri & more.
Get TheHindu Businessline News App on
Recommended Articles